Zealand Pharma receives second part of funding  

2005.09.01
Zealand Pharma, a Danish biopharmaceutical company based near Copenhagen, has received DKK 97 mn (USD 15.8 mn) from new and existing investors, the second part of a total funding of DKK 193 (USD 31.6 mn)

Zealand Pharma, a Danish biopharmaceutical company based near Copenhagen, has received DKK 97 mn (USD 15.8 mn) from new and existing investors, the second part of a total funding of DKK 193 (USD 31.6 mn). Eva Steiness, CEO of Zealand Pharma says the firm has accomplished all the necessary milestones for the second payment. This includes clinical progress of two out-licensed projects to Wyeth and Sanofi-Aventis.

Investors in the second stage of financing comprise both Danish and international players including BankInvest, LD Pensions, Dansk Erhvervsinvestering, the Danish Fund for Industrial Growth, CDC Enterprises Innovation, AGF Private Equity and Life Sciences Partners. The news was reported by national daily newspaper Jyllands-Posten.

Zealand Pharma was founded in 1998. The company focuses on discovery and development of novel peptide based drugs. Zealand's drug discovery has so far resulted in three compounds which are currently in clinical development. One of the compounds, a GLP-1 [Glucagon-Like-Peptide-1 – Ed] analogue for the treatment of Type 2 diabetes, has been licensed to Sanofi-Aventis. A second compound, a gap junction modifier for the prevention of ventricular arrhythmia, has been licensed to Wyeth.

Link > Zealand Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×